What is compounding?
Drug compounding is often regarded as the process of combining or mixing drugs to create a medication tailored to the needs of an individual patient.
The generic form of Vetmedin is Pimobendan.
Vetmedin is in limited supply. Orders placed will be shipped as product continues to come off backorder.
ALTREN for suppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal in mares with ovarian follicles 20 mm or greater. Suppression of estrus will facilitate.
Altren (altrenogest) Solution 0.22% is indicated to suppress estrus in mares. Suppression of estrus allows for a predictable occurrence ofestrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to thephysiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus maybe used to facilitate scheduled breeding during the physiological breeding season.
While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottledispensing tip and connect luer lock syringe (without needle). Draw out appropriate volume of Altren solution. (Note: Do not remove syringewhile bottle is inverted as spillage may result.) Detach syringe and administer solution orally at the rate of 1 mL per 110 pounds of body weight(0.044 mg/kg) once daily for 15 consecutive days. Administer solution directly on the base of the mare's tongue or on the mare's usual grainration. Replace cover on bottle dispensing tip to prevent leakage. Excessive use of a syringe may cause the syringe to stick; therefore, replacesyringe as necessary.
|Approximate Weight Dose in Pounds||Dose in Pounds in mL|
Extensive clinical trials have demonstrated that estrus will be suppressed in approximately 95% of the mares within three days; however, thepost-treatment response depended on the level of ovarian activity when treatment was initiated. Estrus in mares exhibiting regular estrus cyclesduring the breeding season will be suppressed during treatment; these mares return to estrus four to five days following treatment and continueto cycle normally. Mares in winter anestrus with small follicles continued in anestrus and failed to exhibit normal estrus following withdrawal.
Response in mares in the transition phase between winter anestrus and the summer breeding season depended on the degree of follicularactivity. Mares with inactive ovaries and small follicles failed to respond with normal cycles post-treatment, whereas a higher proportion ofmares with ovarian follicles 20 mm or greater in diameter exhibited normal estrus cycles post-treatment. Altren (altrenogest) Solution 0.22%was very effective for suppressing the prolonged estrus behavior frequently observed in mares during the transition period (February, Marchand April). In addition, a high proportion of these mares responded with regular estrus cycles post-treatment.
A 3-year well controlled reproductive safety study was conducted in 27 pregnant mares, and compared with 24 untreated control mares. Treatedmares received 2 mL altrenogest solution 0.22%/110 lb body weight (2x dosage recommended for estrus suppression) from day 20 to day 325of gestation. This study provided the following data:
For oral use in horses only. Keep this and all other medications out of the reach of children. Do not use in horses intended for humanconsumption.
Skin contact must be avoided as Altren (altrenogest) Solution 0.22% is readily absorbed through unbroken skin. Protective glovesmust be worn by all persons handling this product. Pregnant women or women who suspect they are pregnant should not handleAltren (altrenogest) Solution 0.22%. Women of childbearing age should exercise extreme caution when handling this product.Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Direct contact with the skinshould therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.
Warning: Altren (altrenogest) Solution 0.22% is readily absorbed by the skin. Skin contact must be avoided; protective gloves mustbe worn when handling this product.
There has been no human use of this specific product. The information contained in this section is extrapolated from data available on otherproducts of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity ofaltrenogest.
Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such asdisruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy andheadaches. The oil base may also cause complications if swallowed.
In addition, the list of people who should not handle this product (see below) is based upon the known effects of progestins used in humans on achronic basis.
Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest shouldnot penetrate intact rubber or impervious gloves; however, if there is leakage (i.e., pinhole, spillage, etc.), the contaminated area covered bysuch occlusive materials may have increased absorption. The following measures are recommended in case of accidental exposure.
Skin Exposure: Wash immediately with soap and water.
Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention.
If Swallowed: Do not induce vomiting. Altren (altrenogest) Solution 0.22% contains an oil. Call a physician. Vomiting should be supervisedby a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to thephysician.
Store at or below 25°C (77°F). Reclose tightly.